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ABSTRACT
Background: Only a small proportion of preclinical research (research performed in
animal models prior to clinical trials in humans) translates into clinical benefit in
humans. Possible reasons for the lack of translation of the results observed in
preclinical research into human clinical benefit include the design, conduct, and
reporting of preclinical studies. There is currently no formal domain-based
assessment of the clinical relevance of preclinical research. To address this
issue, we have developed a tool for the assessment of the clinical relevance of
preclinical studies, with the intention of assessing the likelihood that therapeutic
preclinical findings can be translated into improvement in the management of
human diseases.
Methods: We searched the EQUATOR network for guidelines that describe the
design, conduct, and reporting of preclinical research. We searched the references of
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these guidelines to identify further relevant publications and developed a set of
domains and signalling questions. We then conducted a modified Delphi-consensus
to refine and develop the tool. The Delphi panel members included specialists in
evidence-based (preclinical) medicine specialists, methodologists, preclinical animal
researchers, a veterinarian, and clinical researchers. A total of 20 Delphi-panel
members completed the first round and 17 members from five countries completed
all three rounds.
Results: This tool has eight domains (construct validity, external validity, risk of
bias, experimental design and data analysis plan, reproducibility and replicability
of methods and results in the same model, research integrity, and research
transparency) and a total of 28 signalling questions and provides a framework
for researchers, journal editors, grant funders, and regulatory authorities to assess
the potential clinical relevance of preclinical animal research.
Conclusion: We have developed a tool to assess the clinical relevance of preclinical
studies. This tool is currently being piloted.
Subjects Clinical Trials, Drugs and Devices, Evidence Based Medicine, Science and Medical
Education
Keywords Preclinical studies, Experimental studies, Animal studies, Clinical relevance
INTRODUCTION
Only a small proportion of preclinical research (research performed on animals prior to
clinical trials) translates into clinical benefit in humans. In a study evaluating the
translation of preclinical research into clinical benefit, a total of 101 technologies
(including drugs, devices, and gene therapy) were assessed in preclinical models and
considered to be promising. Of these, 27 (27%) were subsequently tested in human
randomised clinical trials within 20 years of their preclinical publication. Of these 27
human translational attempts, only one technology resulted in clinical benefit (1%; 95%
confidence interval [0.2–5.4]) (Contopoulos-Ioannidis, Ntzani & Ioannidis, 2003).
In a 2014 report, of 100 potential drugs giving objective improvement when evaluated
in a commonly used mouse model for the treatment of amyotrophic lateral sclerosis,
none were found to be clinically beneficial (Perrin, 2014). Finally, a systematic review
found that there were significant differences in the estimates of treatment effectiveness in
animal experiments compared to that observed in human randomised controlled trials
with some interventions being beneficial in animals but harmful in humans (Perel et al.,
2007). Some of the reasons for the lack of translation of the beneficial results observed
in preclinical research into human clinical benefit could relate to the design, conduct,
and reporting of preclinical studies (Collins & Tabak, 2014; Begley & Ioannidis, 2015;
Ioannidis, 2017). Further information of the reasons and explanations for the lack of
translation of the beneficial results observed in preclinical research into human clinical
benefit is provided under the explanations for the relevant domains and signalling
questions.
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Why is this project needed?
A domain-based tool is a tool that assesses different aspects that impact the outcome of
interest (in this case, clinical relevance of preclinical research). Such domain-based
tools are preferred by methodologists to assess clinical studies (Higgins & Green, 2011;
Whiting et al., 2011, 2016; Sterne et al., 2016); however, as indicated below, no such tool
exists to assess the potential clinical relevance of preclinical research.
Aim of this project
The aim of this project was to design a domain-based tool to assess the clinical relevance
of a preclinical research study in terms of the likelihood that therapeutic preclinical
findings can be translated into improvement in the management of human diseases.
As part of the process, the scope and applicability of this tool was defined to include only in
vivo animal interventional studies.
Who is this intended for?
This tool is intended for all preclinical researchers and clinical researchers considering
translation of preclinical findings to first-in-human clinical trials, the funders of such
studies, and regulatory agencies that approve first-in-human studies.
MATERIALS AND METHODS
We followed the Guidance for Developers of Health Research Reporting Guidelines
(Moher et al., 2010) as there is no specific guidance for developers of tools to assess
clinical relevance of preclinical tools. The registered protocol is available at http://doi.org/
10.5281/zenodo.1117636 (Zenodo registration: 1117636). The study did not start until
the protocol for the current study was registered. The overall process is summarised in
Fig. 1.
Search methods
First, we established whether there is any domain-based assessment tool for preclinical
research. We searched the EQUATOR Network’s library of reporting guidelines using the
terms ‘animal’ or ‘preclinical’ or ‘pre-clinical’. We included any guidelines or tools that
described the design, conduct, and reporting of preclinical research. We searched the
references of these guidelines to identify further relevant publications. We searched only
the EQUATOR Network’s library as it contains a comprehensive search of the existing
reporting guidelines. A scoping search of Pubmed using the terms ‘animal[tiab] AND
(design[tiab] OR conduct[tiab] OR report[tiab])’ returned nearly 50,000 records and
initial searching of the first 1,000 of them did not indicate any relevant publications.
Therefore, the more efficient strategy of searching the EQUATOR Network’s library was
used to find any publications of a domain-based tool related to design, conduct, or
reporting guidelines of preclinical research.
Development of domains and signalling questions
We recorded the topics covered in the previous guidance on preclinical research to develop
a list of domains and signalling questions to be included in the formal domain-based
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assessment of preclinical research. The first author identified and included all the
topics covered in each of the publications and combined similar concepts. The initial
signalling questions were developed after preliminary discussions with and comments
from the all the Delphi panel members (please see below) prior to finalising the initial
list of signalling questions. The full list of the topics covered in the publications and the
initial signalling questions are available in the Supplemental Information Appendix 1
(second column). The signalling questions are questions that help in the assessment of a
Pre-Delphi




*Rank existing domains and signalling 
questions
*Add new domains and signalling questions
*Refine domains and signalling questions
Second round Delphi
*Retain rank or change rank based on others' 
ranking and comments
*Refine domains and signalling questions
Third round Delphi
*Retain rank or change rank based on others' 
ranking and comments
*Refine domains and signalling questions
Post-Delphi
*Include only domains and signalling 
questions if consensus is reached
*Combine or split questions according to the 
most preferred option
*Resolve the explanation statements and 
combining or splitting questions by iterative 
electronic communications 
Figure 1 Overall process. The outline of the process is shown in this figure. A total of three rounds were
conducted. Consensus agreement was reached when at least 70% of panel members strongly agreed
(scores of 7 or more) to include the domain or signalling question.
Full-size DOI: 10.7717/peerj.10673/fig-1
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domain. Additional details about how domains and signalling questions can be used are
listed in Box 1.
Box 1
1. Signalling questions are questions that help in the assessment about a domain. As such,
the overall domain assessment is more important that the answers for individual
signalling questions.
2. Depending upon the nature and purpose for the research, certain domains may be more
important than the other. For example, if the purpose is to find out whether there is
enough information to perform a first-in-human study, the clinical translatability and
reproducibility domain is of greater importance than if the report was about the first
interventional study on a newly developed experimental model.
Selection of experts and consensus
Next, we approached experts in the field of preclinical and clinical research to participate
in the development process. The group of experts were purposively sampled using
snowballing principles (used to identify people with a rich knowledge base on a topic)
(Heckathorn, 2011): people who perform only preclinical research, people who perform
only clinical research, people who perform both preclinical and clinical research, and
methodologists, all of whom had interest in improving the clinical relevance of preclinical
research were approached and asked to suggest other experts who could contribute to
the process. We conducted a modified Delphi-consensus method to refine and develop
the tool. The Delphi-consensus method was based on that described by Jones & Hunter
(1995). The steps in the Delphi process is shown in box 2. All were completed electronically
using an excel file.
Box 2
1. The first round included questions regarding scope and necessity (i.e. should the tool
include all types of preclinical research or only preclinical in vivo animal research and
whether a domain or signalling question should be included in the final tool) in
addition to the signalling questions available in the second column of Appendix 1.
2. The signalling questions were already classified into domains and were supported by
explanations and examples in the first Delphi round. The original classification of
signalling questions is available in Appendix 1.
3. The Delphi panel ranked the questions by importance on a scale of 1–9 with 1 being of
lowest importance and 9 being highest importance.
4. The ranking scores were then grouped into three categories: 1–3 being strong
disagreement about the importance of the question, 4–6 being weak to moderate
agreement about the question, and 7–9 being strong agreement about the question.
The questions were phrased in such a way that higher scores supported inclusion into
the tool and lower scores indicated exclusion (of the scope, domain, or signalling
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question). Consensus was considered to have been reached when 70% or more
participants scored 7 or more. There is variability in the definition of consensus and
70% or more participants scoring 7 or more is within the previously reported range for
consensus agreement (Sumsion, 1998; Hasson, Keeney & McKenna, 2000; Diamond
et al., 2014). This is a commonly used percentage for defining consensus in the Delphi
process (Kleynen et al., 2014; Kirkham et al., 2017).
5. A total of three rounds were conducted. The panel members were allowed to add new
domains or signalling questions in the first round. The panel members could also
suggest revisions to the existing domains or questions (for example revision of the
explanation, examples, or by combining some domains or questions and splitting
others) in all the rounds.
6. After the first round, the Delphi panel were shown their previous rank for the question
and the median rank (and interquartile range) of questions of the Delphi panel.
In addition, the Delphi panel were also asked to choose the best version of any revisions
to the questions and provide ranks for any additional questions identified in the first
round.
7. The panel members were able to retain or change the rank in each of the rounds after
the first round.
8. For calculation of median and interquartile range of ranks and consensus,
non-responses were ignored.
9. At the end of the third round, the aspects which had been ranked with a score of 7 or
above for necessity by at least 70% of the panel were included in the final tool.
10. There was no restriction on the Delphi panel to consult others while ranking the
questions. However, only one final response on the set of questions was accepted from
each Delphi panel member.
Then, we refined the signalling questions and explanation by iterative electronic
communications. Finally, we piloted the tool in biomedical researchers who perform
animal preclinical research and those who perform first-in-human studies to clarify the
signalling questions and explanations.
RESULTS
Deviations from protocol
There were two deviations from our protocol. Firstly, we did not exclude questions even
when consensus was reached on the necessity of the questions: this was because the
phrasing of the domain/signalling question, the explanation, the domain under which the
signalling question is located, and combining or splitting the domains were still being
debated. Secondly, we did not conduct an online meeting of the panel members between
the second and third rounds of the Delphi process because listing and summarising the
comments from different contributors achieved the aim of providing information to justify
or revise the ranking.
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Search results
Twenty-one publications were identified (Idris et al., 1996; Sena et al., 2007; Bath,
Macleod & Green, 2009; Fisher et al., 2009; Macleod et al., 2009; Bouxsein et al., 2010;
Hooijmans, Leenaars & Ritskes-Hoitinga, 2010; Kilkenny et al., 2010; Van der Worp et al.,
2010; Begley & Ellis, 2012; Landis et al., 2012; Hooijmans et al., 2014; National Institutes of
Health, 2014; Perrin, 2014; Bramhall et al., 2015; Czigany et al., 2015; Andrews et al., 2016;
Biophysical Journal, 2017; Open Science Framework, 2017; Osborne et al., 2018; Smith et al.,
2018). The main topics covered in these publications were bias, random errors,
reproducibility, reporting, or a mixture of these elements which result in lack of translation
of preclinical research into clinical benefit. One publication was based on a consensus
meeting (Andrews et al., 2016) and five were based on expert working groups (Hooijmans,
Leenaars & Ritskes-Hoitinga, 2010; Kilkenny et al., 2010; Landis et al., 2012; National
Institutes of Health, 2014; Osborne et al., 2018); and the remaining were opinions of the
authors (Idris et al., 1996; Sena et al., 2007; Bath, Macleod & Green, 2009; Fisher et al., 2009;
Macleod et al., 2009; Bouxsein et al., 2010; Van der Worp et al., 2010; Begley & Ellis, 2012;
Hooijmans et al., 2014; Perrin, 2014; Bramhall et al., 2015; Czigany et al., 2015; Biophysical
Journal, 2017; Open Science Framework, 2017; Smith et al., 2018). All five publications
based on consensus meeting or expert working groups were reporting guidelines
(Hooijmans, Leenaars & Ritskes-Hoitinga, 2010; Kilkenny et al., 2010; Landis et al., 2012;
National Institutes of Health, 2014; Osborne et al., 2018).
Survey respondents
A total of 20 Delphi-panel members completed the first round and 17 members from
5 countries completed all three rounds. The panel members included specialists
representing a broad scope of stakeholders, including target users that would evaluate
interventions for potential ‘bench-to-bedside’ translation: evidence-based (preclinical)
medicine specialists, methodologists, preclinical researchers, veterinarian, and clinical
researchers from UK, Canada, Denmark, and Netherlands. The mean and standard
deviation age of people who completed was 48.4 and 10.9 at the time of registration of
protocol. Of the 17 respondents completing all the three rounds, 12 were males and
5 were females; eleven of these 17 respondents were Professors or had equivalent
senior academic grade at the time of registration. There were no conflicts of interest for the
survey respondents other than those listed in the “Conflicts of Interest” section of this
document.
The reasons for drop-out included illness (one member) and concerns about the scope
and applicability of the tool (two members). These were aspects that were developed as
part of the process of the registered protocol. Therefore, clarity on the scope and
applicability was available only at the end of the Delphi process and not in the first round
of the Delphi-process.
Domains and signalling questions
The Delphi panel agreed on eight domains, which constitutes the tool. Table 1 lists the
domains and signalling questions for which consensus agreement was reached. The first
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Table 1 Domains and signalling questions.
Domain or signalling question Classification
Domain 1: Clinical translatability of results to human disease or condition (construct validity) Low concern/Moderate concern/High concern
1.1 Did the authors use a model that adequately represents the human disease? ‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
1.2 Did the authors sufficiently identify and characterise the model? ‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
1.3 Were the method and timing of the intervention in the specific model relevant to humans? ‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
1.4 If the study used a surrogate outcome, was there a clear and reproducible relationship between an
intervention effect on the surrogate outcome (measured at the time relationship chosen in the
preclinical research) and that on the clinical outcome?
‘Not applicable’/‘Yes’/‘Probably yes’/‘Probably
no’/‘No’/‘No information’
1.5 If the study used a surrogate outcome, did previous experimental studies consistently




1.6 Did a systematic review with or without meta-analysis demonstrate that the effect of an
intervention or a similar intervention on a preclinical model was similar to that in humans?
‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
Domain 2: Experimental design and analysis Low concern/Moderate concern/High concern
2.1 Did the authors describe sample size calculations? ‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
2.2 Did the authors plan and perform statistical tests taking the type of data, the distribution of data,
and the number of groups into account?
‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
2.3 Did the authors make adjustment for multiple hypothesis testing? ‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
2.4 If a dose-response analysis was conducted, did the authors describe the results? ‘Not applicable’/‘Yes’/‘Probably yes’/‘Probably
no’/‘No’/‘No information’
2.5 Did the authors assess and report accuracy? ‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
2.6 Did the authors assess and report precision? ‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
2.7 Did the authors assess and report sampling error? ‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
2.8 Was the measurement error low or was the measurement error adjusted in statistical analysis? ‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
Domain 3: Bias (internal validity) Low concern/Moderate concern/High concern
3.1 Did the authors minimise the risks of bias such as selection bias, confounding bias, performance
bias, detection bias, attrition bias, and selective outcome reporting bias?
‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
Domain 4: Reproducibility of results in a range of clinically relevant conditions (external
validity)
Low concern/Moderate concern/High concern




4.2 Were the results consistent across a range of clinically relevant variations in the model? ‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
4.3 Did the authors report take existing evidence into account when choosing the comparators? ‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
Domain 5: Reproducibility and replicability of methods and results in the same model Low concern/Moderate concern/High concern
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four domains relate to the study design and analysis that are within the control of the
research team (clinical translatability of results to human disease or condition
(construct validity)), experimental design and data analysis, bias (internal validity), and
reproducibility of results in a different disease-specific model (external validity). The fifth
domain relates to replicability of results for which the research team may have to rely
on other research teams (reproducibility and replicability of methods and results in the
same model); however, these aspects can be integrated as part of the same study. The sixth
domain relates to study conclusions which considers the study design, analysis, and
reproducibility and replicability of results. The last two domains relate to factors that
increase or decrease the confidence in the study findings (research integrity and research
transparency).
These eight domains cover a total of 28 signalling questions. The number of questions in
each domain range from 1 to 8, with a median of three questions in each domain. All the
signalling questions have been phrased in such a way that a classification of ‘yes’ or
‘probably yes’ will result in low concerns about the clinical relevance of the study for the
domain.
Scope and applicability of the tool
The scope of the tool is only for assessment of the clinical relevance of a preclinical
research study in terms of the likelihood that therapeutic preclinical findings can be
Table 1 (continued)
Domain or signalling question Classification
5.2 Did an independent group of researchers replicate the experimental protocols/methods? ‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’




Domain 6: Implications of the study findings (study conclusions) Low concern/Moderate concern/High concern
6.1 Did the authors’ conclusions represent the study findings, taking its limitations into account? ‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’




Domain 7: Research integrity Low concern/Moderate concern/High concern
7.1 Did the research team obtain ethical approvals and any other regulatory approvals required to
perform the research prior to the start of the study?
‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
7.2 Did the authors take steps to prevent unintentional changes to data? ‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
Domain 8: Research transparency Low concern/Moderate concern/High concern
8.1 Did the authors describe the experimental procedures sufficiently in a protocol that was
registered prior to the start of the research?
‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
8.2 Did the authors describe any deviations from the registered protocol? ‘Yes’/‘Probably yes’/‘Probably no’/‘No’/‘No
information’
8.3 Did the authors provide the individual subject data along with explanation for any numerical
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translated into improvement in the management of human diseases and not for
assessment of the quality of the study, that is how well the study was conducted, although
we refer to tools that assess how well the study was conducted. It is important to make
this distinction as even a very well-designed and conducted preclinical study may not
translate to improvement in the management of human diseases, as is the case of clinical
research.
As part of the Delphi process, the scope was narrowed to include only in vivo laboratory
based preclinical animal research evaluating interventions. Therefore, our tool is not
intended for use on other forms of preclinical research such as in vitro work (e.g. cell
cultures), in silico research, or veterinary research. This tool is not applicable in the
initial exploratory phase of development of new animal models of disease, although the
tool is applicable in interventional studies using such newly developed models.
The domains and signalling questions in each round of the Delphi process and
post-Delphi process are summarised in Fig. 2.
Classification of signalling questions and domains
Consistent with existing domain based tools, responses to each signalling question can be
classified as ‘yes’, ‘probably yes’, ‘probably no’, ‘no’, or ‘no information’ (Sterne et al., 2016;
Whiting et al., 2016), depending upon the information described in the report or after
obtaining the relevant information from the report’s corresponding author, although
the study authors may provide answers that the assessor asks because of cognitive bias.
A few questions can also be classified as ‘not applicable’. These questions start with the
phrase ‘if’. For classification of the concerns in the domain, such questions are excluded
from the analysis.
A domain can be classified as ‘low concern’ if all the signalling questions under the
domain were classified as ‘yes’ or ‘probably yes’, ‘high concern’ if any of the signalling
questions under the domain were classified as ‘no’ or ‘probably no’, and as ‘moderate
concern’ for all other combinations.
Overall classification of the clinical relevance of the study
A study with ‘low concerns’ for all domains will be considered as a study with high clinical
relevance in terms of translation of preclinical results with similar magnitude and direction
of effect to improve management of human diseases. A study with unclear or high
concerns for one or more domains will be considered as a study with uncertain clinical
relevance in terms of translation of preclinical results with similar magnitude and direction
of effect to improve management of human diseases.
However, depending upon the nature and purpose for use of the research, certain
domains may be more important than the others, and the users can decide in advance
whether a particular domain is important (or not). For example if the purpose is to
find out whether there is enough information to perform a first-in-human study, the
clinical translatability and reproducibility domain is of greater importance than if the
report was about the first interventional study on the model.
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At the design and conduct stage, researchers, funders, and other stakeholders can
specifically look at the domains that are assessed as unclear or high concern and improve
the design and conduct to increase the clinical relevance. At the reporting stage,
researchers, funders, and other stakeholders can use this tool to design, fund, or give
approval for further research.
Practical use of the tool
The tool should be used with a clinical question in mind. This should include the
following aspects of the planned clinical study as a minimum: population in whom
the intervention or diagnostic test is used, intervention and control, and the outcomes
(PICO).
Figure 2 Flow of domains and signalling questions. Full-size DOI: 10.7717/peerj.10673/fig-2
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We recommend that the tool is used after successfully completing the training
material, which includes examples of how the signalling questions can be answered and
assessment of understanding the use of the tool (the training material is available at:
https://doi.org/10.5281/zenodo.4159278) and at least two assessors using the tool
independently.
A schema for the practical use of the tool is described in Fig. 3.
Scoring
The tool has not been developed to obtain an overall score for clinical relevance
assessment. Therefore, modifying the tool by assigning scores to individual signalling
questions or domains is likely to be misleading.
Panel agreement
Appendix 1 summarises the Delphi panel agreement on the different domains and
signalling questions. As shown in the Appendix 1, the domains, the signalling questions,
and the terminologies used have improved significantly from the starting version of the
tool. Appendix 1 also demonstrates that there was a change in the agreement in the
questions indicating that the panel members were receptive to others’ views while ranking
the questions.
Phase 2: Assessment phase
Assessment of planned preclinical animal 
study
Signalling quesons, domains, and overall 
clinical relevance
Preclinical study: high clinical 
relevance
Assessment of Completed preclinical 
animal study
Signalling quesons, domains, and overall 
clinical relevance
Phase 3: Decision phase
Fund, approve, conduct 
preclinical study
Phase 1: Preparatory phase 





Phase 3: Decision phase
Reject current study and redesign 
preclinical study
Preclinical study: high clinical 
relevance
Phase 3: Decision phase
Fund, approve, conduct 
clinical study
Phase 3: Decision phase




Figure 3 Schema for use of the tool. Full-size DOI: 10.7717/peerj.10673/fig-3
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RATIONALE AND EXPLANATION OF DOMAINS AND
SIGNALLING QUESTIONS
Domain 1: clinical translatability of results to human disease or
condition (construct validity)
The purpose of this domain is to assess whether statistically positive results in the reports
of the preclinical animal research studies could result in clinical benefit. This evaluation
focuses on both primary outcomes and secondary outcomes, or the ‘main findings’ if
the reports do not explicitly declare primary and secondary outcomes.
1.1 Did the authors use a model that adequately represents the human
disease?
This question assesses biological plausibility. We have used the term ‘model’ to refer to the
animal model used as a substitute for human disease, for example a mouse model of
multiple myeloma. We have also used this term to refer to induction methods in animals
in a non-diseased state that progress to a diseased state, for example a rat model of
behavioural alterations (forced swim test) mimicking depression (Yankelevitch-Yahav
et al., 2015), or animals which have been exposed to a treatment even if they did not have
any induced human disease, for example a rabbit model of liver resection, a canine model
of kidney transplantation. Studies have shown that animal researchers frequently use
disease models that do not adequately represent or relate to the human disease (De Vries
et al., 2012; Sloff et al., 2014a, 2014b; Zeeff et al., 2016).
Specific characteristics to consider include species and/or strain used, age, immune
competence, and genetic composition as relevant. Other considerations include different
methods of disease induction in the same or different species.
This signalling question considers whether the researchers reporting the results
(‘authors’) have described on information such as characteristics of model, different
methods of disease induction (if appropriate), and biological plausibility while choosing
the model, and have the researchers provided evidence for the choice of animal model.
The assessment of these questions may require subject content expertise.
1.2 Did the authors identify and characterise the model?
This question assesses whether after choosing the appropriate model (species, sex,
genetic composition, age), the authors have performed studies to characterise the
model. For example sepsis is often induced through caecal ligation and puncture; however,
the effects of this procedure can produce variable sepsis severity. Another example is
when genes that induce disease may not be inherited reliably: the resulting disease
manifestation could be variable and interventions may appear to be less effective or more
effective than they actually are (Perrin, 2014). Therefore, it is important to ensure that the
genes that induce the disease are correctly identified and that such genes are inherited.
Another example is when the authors want to use a knockout model to understand
the mechanism of how an intervention works based on the assumption that the only
difference between the knockout mice and the non-knockout mice is the knockout gene.
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However, the animals used may still contain the gene that was intended to be removed or
the animals may have other genes introduced during the process of creating the
knockout mice (Eisener-Dorman, Lawrence & Bolivar, 2009). Therefore, it is important
to understand and characterise the baseline model prior to testing an experimental
intervention.
1.3 Were the method and timing of the intervention in the specific model
relevant to humans?
For pharmacological or biological interventions, this question refers to the dose and
route of administration. For other types of interventions, such as surgery or device
implementation, the question refers to whether the method used in the animal model is
similar to that in humans.
For pharmacological interventions, there may be a therapeutic dose and route which is
likely to be safe and effective in humans. It is unlikely that the exact dose used in animals
is studied in humans, at least in the initial human safety studies. Therefore, dose
conversion is used in first-in-human studies. Simple practice guides and general guidance
for dose conversion between animals and humans are available (United States Food and
Drug Administration, 2005; Nair & Jacob, 2016; European Medicines Agency (EMA), 2017).
However, some researchers may use doses in animals at levels that would be toxic when
extrapolated to humans and therefore unlikely to be used. Dose conversion guides (Nair &
Jacob, 2016) can help with the assessment of whether the dose used is likely to be toxic.
The effectiveness of an intervention at such toxic doses is not relevant to humans. It is
preferable to use the same route of administration for animal studies as planned in
humans, since different routes may lead to different metabolic fate and toxicity of the drug.
For non-pharmacological interventions for which similar interventions have not
been tested in humans, feasibility of use in humans should be considered. For example
thermal ablation is one of the treatment options for brain tumours. Ablation can, for
example also be achieved by irreversible electroporation, which involves passing high
voltage electricity and has been attempted in human liver and pancreas (Ansari et al., 2017;
Lyu et al., 2017). However, the zone affected by irreversible electroporation has not
been characterised fully: treatment of human brain tumours using this technique can
only be attempted when human studies confirm that there are no residual effects of
high voltage electricity in the surrounding tissue (not requiring ablation). Until then, the
testing of irreversible electroporation in animal models of brain tumours is unlikely to
progress to human trials and will not be relevant to humans regardless of how effective it
may be.
The intervention may also be effective only at a certain time point in the disease
(i.e. ‘therapeutic window’). It may not be possible to recognise and initiate treatment
during the therapeutic window because of the delays in appearance of symptoms and
diagnosis. Therefore, there is no rationale in performing preclinical animal studies in
which the intervention cannot be initiated during the likely therapeutic window.
Finally, the treatment may be initiated prior to induction of disease in animal models:
this may not reflect the actual use of the drug in the human clinical situation.
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1.4 If the study used a surrogate outcome, was there a clear and reproducible
relationship between an intervention effect on the surrogate outcome
(measured at the time chosen in the preclinical research) and that on the
clinical outcome?
A ‘surrogate outcome’ is an outcome that is used as a substitute for another (more direct)
outcome along the disease pathway. For example in the clinical scenario, an improvement
in CD4 count (surrogate outcome) leads to a decrease in mortality (clinical outcome)
in people with human immune deficiency (HIV) (Bucher et al., 1999). The relationship
between the effect of the intervention (a drug that improves the CD4 count) on the
surrogate outcome (CD4 count) and a clinical outcome (mortality after HIV infection)
should be high, should be shown in multiple studies, and should be independent of the
type of intervention for a surrogate outcome to be valid (Bucher et al., 1999). This probably
applies to preclinical research as well. For example the relationship between the effect of
an intervention (a cancer drug) on the surrogate outcome (apoptosis) and a clinical
outcome or its animal equivalent (for example mortality in the animal model) should be
high, shown in multiple studies and independent of the type of intervention for a surrogate
outcome to be valid in the preclinical model.
If the surrogate outcome is the only pathway or the main pathway between the disease,
intervention, and the clinical outcome (or its animal equivalent) (Fig. 4), the surrogate
outcome is likely to be a valid indirect surrogate outcome (Fleming & DeMets, 1996).
This, however, should be verified in clinical studies. For example preclinical animal
research studies may use gene or protein levels to determine whether an intervention is
effective. If the gene (or protein) lies in the only pathway between the disease and
animal equivalent of the clinical outcome, a change in expression, levels, or activity of the
gene (or protein) is likely to result in an equivalent change in the animal equivalent of
the clinical outcomes. To simplify this even further this signalling question can be
simplified to the context in which it is used for example ‘Is apoptosis at 24 h (surrogate
outcome) in the preclinical animal model correlated with improved survival in animals
(animal equivalent of a clinical outcome)’? Another example of this signalling question
simplified to the context of the research can be ‘Are aberrant crypt foci (surrogate
outcome) in animal models correlated to colon cancer in these models (animal equivalent
of a clinical outcome)’?
This signalling question assesses whether the authors have provided evidence for
the relationship between surrogate outcome and the clinical outcome (or its animal
equivalent). There is currently no guidance as to what a high level of association is in
terms of determining the relationship between surrogate outcomes and the clinical
outcomes (or its animal equivalent). Some suggestions are mentioned in Appendix 2.
1.5 If the study used a surrogate outcome, did previous experimental studies
consistently demonstrate that change in surrogate outcome(s) by a treatment
led to a comparable change in clinical outcomes?
This question aims to go further than the evaluation of association between surrogate
outcome and the clinical outcome (or its animal equivalent). A simple association between
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a surrogate outcome and clinical outcome may be because the surrogate outcome may
merely be a good predictor. For example sodium fluoride caused more fractures despite
increasing bone mineral density, even though, low bone mineral density is associated with
increased fractures (Bucher et al., 1999). If a change in the surrogate outcome by a
Figure 4 Situation when a surrogate outcome is likely to be valid. (A) The surrogate outcome is the
only pathway that the disease can cause the clinical outcome. (B) The intervention acts in this pathway
and causes a change in surrogate outcome, leading to a change in the clinical outcome. (C) If there are
other pathways (which are not affected by the intervention) through which the disease can cause the
clinical outcome, then the validity of the surrogate outcome will be decreased. If the intervention affects
the clinical outcome through pathways unrelated to the surrogate outcome, then the validity of the
surrogate outcome will be decreased. Full-size DOI: 10.7717/peerj.10673/fig-4
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treatment results in a comparable change in the clinical outcome (or its animal equivalent),
the surrogate outcome is likely to be a valid surrogate outcome (Fig. 4). This change has to
be consistent, that is, most studies showing that a treatment results in a comparable
improvement in the clinical outcome (or its animal equivalent). Note that it is possible
that there may not a fully comparable change, for example a 50% improvement in the
surrogate outcome may result only in a 25% improvement in the animal equivalent of
the clinical outcome. In such situations, it is possible to use the ‘proportion explained’
approach proposed by Freedman, Graubard & Schatzkin (1992), a concept which was
extended to randomised controlled trials and systematic reviews by Buyse et al. (2000).
This involves calculating the association between the effect estimates of the surrogate
outcome and clinical outcome (or its animal equivalent) from the different trials or
centres within a trial (Buyse et al., 2000) (although, one can obtain a more reliable estimate
of this association using individual participant data) (Tierney et al., 2015).
Generally, few surrogate outcomes are validated substitutes for clinical outcomes: an
example of a valid surrogate outcome is CD4 count in people with human immune
deficiency (HIV) (Bucher et al., 1999). Even if an association exists between the surrogate
outcome and the clinical outcome, failure to demonstrate that changes in surrogate
outcome by a treatment led to changes in clinical outcome can have disastrous effects
(Bucher et al., 1999; Yudkin, Lipska & Montori, 2011; Kim & Prasad, 2015; Rupp &
Zuckerman, 2017) (Appendix 3).
1.6 Did a systematic review with or without meta-analysis demonstrate that
the effect of an intervention or a similar intervention in animal model was
similar to that in humans?
The best way to find consistent evidence to support or refute the validity of surrogate
outcomes (covered in the previous signalling questions) and the comparability of the
animal equivalent of the clinical outcomes to that in humans is by systematic reviews.
For example if an intervention results in better functional recovery in a mouse model of
stroke, then does it also result in better functional recovery in humans with stroke?
If so, other interventions can be tested in this model. Systematic reviews help in calculating
the association between the effect estimates of the surrogate outcome and clinical
outcome (or its animal equivalent) from the different trials or centres within a trial, as
mentioned previously (Buyse et al., 2000).
Failure to conduct a systematic review of preclinical studies prior to the start of the
clinical research and presenting selective results to grant funders or patients is scientifically
questionable, likely to be unethical, and can lead to delays in finding suitable treatments
for diseases by investing resources in treatments that could have been predicted to fail
(Cohen, 2018; Ritskes-Hoitinga &Wever, 2018). Therefore, this signalling question assesses
whether the authors provide evidence from systematic reviews of preclinical animal
research studies and clinical studies that the intervention or a similar intervention showed
treatment effects that were similar in preclinical research studies and clinical studies in
humans.
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Domain 2: experimental design and data analysis plan
The purpose of this domain is to assess the experimental study design and assess the
analysis performed by the authors with respect to random errors and measurement errors.
There are very good online resources that can help with the experimental design and
statistical analysis in preclinical studies (Bate & Clark, 2014; Festing, 2016; Nature
Collection, 2018). These resources can help in the assessment of this domain.
2.1 Did the authors describe sample size calculations?
Sample size calculations are performed to control for random errors (i.e. ensure that a
difference of interest can be observed) and should be used in preclinical studies that
involve hypothesis testing (for example a study conducted to find out whether a treatment
is likely to result in benefit). This signalling question assesses whether the authors have
described the sample size calculations to justify the number of animals used to reliably
answer the research question.
2.2 Did the authors plan and perform statistical tests taking the type of data,
the distribution of data, and the number of groups into account?
The statistical tests that are performed depend upon the type of data (for example
categorical nominal data, ordinal data, continuous quantitative data, continuous
discrete data), distribution of data (for example normal distribution, binomial distribution,
Poisson distribution, etc.), and the number of groups compared. The authors should justify
the use of statistical tests based on the above factors. The hypothesis testing should be
pre-planned. This signalling question assesses whether the authors planned and performed
statistical tests taking type of data, distribution of data, and the number of groups
compared into account.
The authors may use multivariable analysis (analysis involving more than one predictor
variable) or multivariate analysis (analysis involving more than one outcome variable),
although these terms are often used interchangeably (Hidalgo & Goodman, 2013). Some
assumptions about the data are made when multivariable analysis and multivariate
analysis are performed (Casson & Farmer, 2014; Nørskov et al., 2020) and the results are
reliable only when these assumptions are met. Therefore, assessment of whether the
authors have reported about the assumptions should be considered as a part of this
signalling question.
The authors may have also performed unplanned hypothesis testing after the data
becomes available, which is a form of ‘data dredging’ and can be assessed in the next
signalling question. The authors may also have made other changes to the statistical plan.
This aspect can be assessed as part of signalling question 8.2.
2.3 Did the authors make adjustment for multiple hypothesis testing?
This signalling question assesses whether study authors have made statistical plans to
account for multiple testing.
When multiple hypotheses are tested in the same research, statistical adjustments
are necessary to achieve the planned alpha and beta errors. Testing for more than two
groups is a form of multiple testing: the statistical output usually adjusts for more than two
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groups. However, testing many outcomes is not usually adjusted in the statistical
software output and has to be adjusted manually (or electronically) using some form
of correction. This is not necessary when the study authors have a single primary outcome
and base their conclusions on the observations on the single primary outcome. However,
when multiple primary outcomes are used, adjustments for multiple hypothesis testing
should be considered (Streiner, 2015). For example if the effectiveness of a drug
against cancer is tested by apoptosis, cell proliferation, and metastatic potential, authors
should consider statistical adjustments for multiple testing.
Multiple analyses of the data with the aim of stopping the study once statistical
significance is reached and data dredging (multiple unplanned subgroup analyses to
identify an analysis that is statistically significant; other names include ‘P value fiddling’ or
‘P-hacking’) are other forms of multiple testing and should be avoided (Streiner, 2015).
Methods for interim analysis to guide stopping of clinical trials such as sequential and
group sequential boundaries have been developed (Grant et al., 2005). Implementation of
group sequential designs may improve the efficiency of animal research (Neumann et al.,
2017).
2.4 If a dose-response analysis was conducted, did the authors describe the
results?
In pharmacological testing in animals, it is usually possible to test multiple doses of a drug.
This may also apply to some non-pharmacological interventions, where one can test the
intervention at multiple frequencies or duration (for example exercise for 20 min vs
exercise for 10 min vs no exercise). A dose-response relationship indicates that the
effect observed is greater with an increase in the dose. Animal studies incorporating
dose-response gradients were more likely to be replicable to humans (Hackam &
Redelmeier, 2006). This signalling question assesses whether the authors have reported the
dose-response analysis if it was conducted.
2.5 Did the authors assess and report accuracy?
Accuracy is the nearness of the observed value (using the method described) to the true
value. Depending upon the type of outcome, these can be assessed by Kappa statistics,
Bland–Altman method, correlation coefficient, concordance correlation coefficient,
standard deviation, or relative standard deviation (Bland & Altman, 1986, 1996a, 1996b,
1996c; Van Stralen et al., 2008; Watson & Petrie, 2010; Zaki et al., 2012). This signalling
question assesses whether the authors have provided a measure of accuracy by using
an equipment for which accuracy information is available, or used a reference material
(material with known values measured by an accurate equipment) to assess accuracy.
2.6 Did the authors assess and report precision?
Precision, in the context of measurement error, is the nearness of values when repeated
measurements are made in the same sample (technical replicates). The same methods
used for assessing accuracy can be used for assessing precision, except that instead of using
a reference material, the comparison is between the measurements made in the same
sample for assessing precision. The width of confidence intervals can also provide a
Gurusamy et al. (2021), PeerJ, DOI 10.7717/peerj.10673 19/36
measure of the precision. This signalling question assesses whether the authors have
measured and reported precision.
2.7 Did the authors assess and report sampling error?
In some situations, errors arise because of the non-homogenous nature of the tissues or
change of values over time, for example diurnal variation. The same methods used to
assess accuracy can be used for assessing sampling error, except that instead of using a
reference material, the comparison is between the measurements made in samples
from different parts of cancer/diseased tissue (biological replicates) or samples from
different times. This signalling question assesses whether the authors have measured and
reported sampling error.
2.8Was themeasurement error low or was themeasurement error adjusted in
statistical analysis?
This signalling question assesses whether the measurement errors (errors in one or more of
accuracy, precision, sampling error) were low or were reported as adjusted in statistical
analysis. There are currently no universally agreed values at which measurement errors can
be considered low. This will depend upon the context and the measure used to assess
measurement error. For example if the differences between the groups is in cm and
the measurement error is non-differential (i.e. the error does not depend upon the
intervention) and is a fraction of a mm, then the measurement error is unlikely to cause
a major difference in the conclusions. On the other hand, if the measurement error is
differential (i.e. the measurement error depends upon the intervention) or large relative
to the effect estimates, then this has to be estimated and adjusted during the analysis.
Measurement error can be adjusted using special methods such as ANOVA repeated
measurements, general linear model repeated measurements, regression calibration,
moment reconstruction, or simulation extrapolation (Vasey & Thayer, 1987; Carroll, 1989;
Lin & Carroll, 1999; Littell, Pendergast & Natarajan, 2000; Freedman et al., 2004, 2008).
Domain 3: Bias (internal validity)
Even if an animal model with good construct validity is chosen, biases such as selection
bias, confounding bias, performance bias, detection bias, and attrition bias can decrease
the value of the study (Higgins & Green, 2011). The purpose of this domain is to assess the
risks of bias in the study.
3.1 Did the authors minimise the risks of bias such as selection bias,
confounding bias, performance bias, detection bias, attrition bias, and
selective outcome reporting bias?
Some sources, examples, and rationale for the risk of bias in animal studies are available
in the SYRCLE’s risk of bias assessment tool for animal research, National Research
Council’s guidance of description of animal research in scientific publications, US National
Institute of Neurological Disorders and Stroke’s call for transparent reporting, and
National Institute of Health’s principles and guidelines for Reporting Preclinical Research
(National Research Council, 2011; Landis et al., 2012; Hooijmans et al., 2014; National
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Institutes of Health, 2014). These risks of bias should have been minimised in the study.
While many researchers are familiar with most of these types of bias, selective outcome
reporting warrants further discussion. Selective outcome reporting is a form of bias where
study authors selectively report the results that favour the intervention. The selective
outcome reporting bias should, as a minimum, cover whether the choice of results to be
reported (in tables, text, or figures) were predetermined. Changing the outcomes is
prevalent in human clinical trials (Jones et al., 2015; Altman, Moher & Schulz, 2017;
Howard et al., 2017). There are no studies that investigate the prevalence of changing the
outcomes in preclinical animal research; however, one can expect that it is at least as
prevalent in preclinical animal research as in clinical research. It is now also possible to
register preclinical animal studies at www.preclinicaltrials.eu and www.osf.io before they
start, which can help with the assessment of selective outcome reporting bias.
In some situations, International Organization for Standardization (ISO) standards
(Chen & Wang, 2018) and National Toxicology Program recommendations (U.S.
Department of Health and Human Services, 2018) may also be applicable.
Domain 4: reproducibility of results in a range of clinically relevant
conditions (external validity)
The purpose of this domain is to assess whether the results were reproduced in a range of
clinically relevant conditions (different methods of disease induction, different genetic
composition, different ages, sex, etc).
4.1 Were the results reproduced with alternative preclinical models of the
disease/condition being investigated?
The underlying rationale behind preclinical animal research is the genetic, anatomical,
physiological, and biochemical similarities (one or more of the above) between animals
and humans. Different animals have different levels of genetic similarities with humans
and between each other (Gibbs et al., 2004; Church et al., 2009; Howe et al., 2013), which
leads to anatomical, physiological, and biochemical differences between the different
species. This can lead to differences in the treatment effects between different animal
species or different models of induction of disease. The differences may be in the direction
(for example the intervention is beneficial is some species and harmful in others) or in
the magnitude (for example the intervention is beneficial in all the species, but the
treatment effects differ in differ species). Even if the inconsistency is only in the magnitude
of effect, this indicates that the treatment effects in humans may also be different from
those observed in different species. Therefore, consistent treatment effects observed across
different animal species or different models of induction of disease may increase the
likelihood of similar treatment effects being observed in humans. This signalling question
assesses the consistency across different preclinical models.
4.2 Were the results consistent across a range of clinically relevant variations
in the model?
In the clinical setting, a treatment is used in people of different ages, sex, genetic
composition, and with associated comorbidities. These differences within species and
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existing comorbidities can lead to different treatment effects even if the same species and
the model of induction is used. Therefore, this signalling question assesses whether
animals of multiple ages, sex, genetic compositions, and existing comorbidities were used
and whether the treatment effect was consistent across these clinically relevant variations.
4.3 Did the authors report take existing evidence into account when choosing
the comparators?
Researchers may choose an inactive control rather than an established active treatment
as the control to show that a drug is effective. They may also choose a weak control
such as a dose lower than the effective dose or an inappropriate route for control
to demonstrate a benefit of the intervention. Therefore, in these last examples,
experimental results that the intervention is better than control are applicable only for
the comparison of the intervention with a weak control, which may not be clinically
relevant. This signalling question assesses whether the authors chose an established active
treatment at the correct dose or route (in the case of pharmacological interventions) as
control.
Domain 5: reproducibility and replicability of methods and results in
the same model
In a survey of more than 1,500 scientists conducted by Nature, more than 70% of
researchers tried and failed to reproduce another scientist’s experiments, and more than
half failed to reproduce their own experiments (Baker, 2016). About 90% of scientists
surveyed thought that there was a slight or significant ‘reproducibility crisis’ (Baker, 2016).
This domain assesses the reproducibility (the ability to achieve similar or nearly identical
results using comparable materials and methodologies) and replicability (the ability to
repeat a prior result using the same source materials and methodologies) (FASEB, 2016) of
the methods and results in the same animal model and differs from external validity, which
focusses on whether the results were reproduced in a different clinically relevant model.
5.1 Did the authors describe the experimental protocols sufficiently to allow
their replication?
One of the methods of improving replication is to describe the experimental protocols
sufficiently. This signalling question assesses whether the authors have described the
experimental protocols sufficiently to allow their replication.
5.2 Did an independent group of researchers replicate the experimental
protocols?
This signalling question is different from the “Did the Authors Describe the Experimental
Protocols Sufficiently to Allow their Replication?”, above. The previous question
assesses whether the protocols were described sufficiently, while this signalling question
assesses whether these protocols were actually replicated by an independent group of
researchers. The independent group of researchers could be part of the author team and
could be from the same or different institutions, as long as they repeated the experiments
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independently. The results of replication of experimental protocols can be part of the same
report, but could also be another report.
5.3 Did the authors or an independent group of researchers reproduce the
results in similar and different laboratory conditions?
This signalling question is different from the “Did the Authors Describe the Experimental
Protocols Sufficiently to Allow their Replication?”, above. The previous question
assesses whether the protocols were protocols could be replicated. This signalling questions
assesses whether the results could be reproduced in similar and different laboratory
conditions. Even when the protocols/methods are replicated by an independent group
of researchers, the results may not be replicated or reproduced in similar and/or different
laboratory conditions (Baker, 2016). This signalling question assesses whether the
results were replicated or reproduced. Attempts to replicate or reproduce the results can be
a part of the same report, but could also be another report, particularly if the attempt to
replicate or reproduce the results is made by an independent group of researchers.
Domain 6: implications of the study findings (study conclusions)
The purpose of the domain is to assess whether the authors have made conclusions that
reflect the study design and results.
6.1 Did the authors’ conclusions represent the study findings, taking its
limitations into account?
This signalling question assesses whether the study authors considered all the
findings and limitations of the study while arriving at conclusions. The study authors may
have made conclusions based on extrapolations of their results and not on their data,
which is poor research practice. This should also be considered while assessing this
signalling question. Studies designed to look at pathophysiology of disease or
mechanism of action of treatment should demonstrate evidence of similarity between
disease process in animal and human disease before arriving at conclusions regarding these
aspects.
6.2 Did the authors provide details on additional research required to conduct
first-in-human studies?
Researchers should consider the limitations of their study before recommending first-in-
human studies. For example this may be the first experimental study on this research
question; therefore, the research question may not have been conducted in multiple
centres. The authors should highlight the need for studies that reproduce the results by
a different group of researchers. If the current study was a study to attempt reproduction of
the results of a previous study, then the authors should clarify whether further preclinical
studies are required or whether the intervention should be evaluated in humans with
justifications: repeating the study in preclinical models can be justified if the intervention
needs to be evaluated after a modification; recommending evaluation in humans can be
justified if efficacy and safety has been demonstrated consistently in multiple preclinical
models and centres.
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This signalling question assesses whether the study authors have made future
research recommendations based on the study design and results from this study in the
context of other studies on this issue. A study on investigator brochures in Germany
demonstrated that animal study results were not evaluated well, for example by systematic
reviews of animal studies before clinical trials (Wieschowski et al., 2018), highlighting
that the further research recommendations should be made taking other studies on the
topic into account.
Domain 7: research integrity
The purpose of this domain is to ensure that the authors adhered to the principles of
research integrity during the design, conduct and reporting of their research. If the authors
did not adhere to the principles of research integrity, the results can be unreliable even if
the study experimental design and analysis were reliable. Lack of research integrity can
decrease the confidence in the study findings.
7.1 Did the research team obtain ethical approvals and any other regulatory
approvals required to perform the research prior to the start of the study?
Animal research should be performed ethically in a humane way. While university ethics
boards can confirm the existence of ethical approval, additional licencing requirements
(for example Home Office License in UK) may be necessary before the research can be
conducted. This is to ensure that the principles of replacement (methods which avoid or
replace the use of animals), reduction (methods which minimise the number of animals
used per experiment), and refinement (methods which minimise animal suffering and
improve welfare) are followed during scientific research (NC3Rs; UK Government,
1986). In some countries like the UK, preclinical studies conducted to justify human
clinical trials are required to follow Good Laboratory Practice Regulations (UK
Government, 1999). This signalling question assesses whether the study authors have
provided the details of ethics approval or any other regulatory approvals and standards
that they used in their research.
7.2 Did the authors take steps to prevent unintentional changes to data?
Unintentional human errors when handling data (‘data corruption’) has the potential to
affect the quality of study results and a possible reason for lack of reproducibility as
they can cause misclassification of exposure or outcomes (Van den Broeck et al., 2005;
Ward, Self & Froehle, 2015). ‘Data cleaning’ is the process of identifying and correcting
these errors, or at least attempting to minimise the impact on study results (Van den
Broeck et al., 2005). Methods used for data cleaning can have a significant impact on
the results (Dasu & Loh, 2012; Randall et al., 2013). The best way to minimise data errors is
to avoid them in the first place. While there are many ‘data handling’ guidelines about
the protection of personal data, there is currently no guidance on the best method to
avoid ‘data corruption’. The UK Digital Curation Centre (www.dcc.ac.uk) provides expert
advice and practical help to research organisations wanting to store, manage, protect, and
share digital research data. Maintenance of laboratory logs, accuracy measures between
laboratory logs and data used, and use of password-protected data files can all decrease the
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risks of unintentional changes to data. This signalling question assesses whether the
authors took steps to prevent unintentional changes to data.
Domain 8: research transparency
The purpose of this domain is to assess whether the animal study authors were transparent
in their reporting. Transparent reporting increases the confidence in the study findings
and promotes replicability of the research findings. Reporting guidelines such as
ARRIVE guidelines 2.0, Gold Standard Publication Checklist to improve the quality of
animal studies, and National Research Council’s guidance on description of animal
research in scientific publications can help with transparent reporting (Hooijmans,
Leenaars & Ritskes-Hoitinga, 2010; National Research Council, 2011; Percie du Sert
et al., 2020).
8.1 Did the authors describe the experimental procedures sufficiently in a
protocol that was registered prior to the start of the research?
While selective outcome reporting is covered under the bias (internal validity) domain, the
authors may have changed the protocol of the study in various other ways, for example the
disease-specific model, intervention, control, or the methods of administration of the
intervention and control. The experimental protocols should be registered prior to the start
of the study in a preclinical trial registry, such as, https://www.preclinicaltrials.eu/, which
allows registration of animal studies and is searchable. Studies can also be registered in
Open Science Framework (https://osf.io/). Alternatively, posting the protocol in open
access preprint servers such as https://www.biorxiv.org/ or https://arxiv.org/, print or
online journals, in an institutional or public data repository such as https://zenodo.org/ is
another option. The study authors should provide a link to this registered protocol in their
study report.
The focus of this signalling question is about availability of a registered protocol prior
to research commencement, which had enough details to allow replication, while the
signalling question “Did the Authors Describe the Experimental Protocols Sufficiently
to Allow their Replication?” refers to the description of the final protocol used (after all the
modifications to the registered protocol) in sufficient detail to allow replication.
8.2 Did the authors describe any deviations from the registered protocol?
There may be justifiable reasons for alteration from a registered protocol. The authors
should be explicit and describe any deviations from their plans and the reasons for
them. In addition to registries, repositories, and journals for registering preclinical
trials, some journals also offer ‘registered reports’ publishing format, which involves
peer review of the study design and methodology, and if successful, results in a
conditional acceptance for publication prior to the research being undertaken
(Hardwicke & Ioannidis, 2018). This will also allow evaluation of the deviations from
the registered protocol.
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8.3 Did the authors provide the individual subject data along with explanation
for any numerical codes/substitutions or abbreviations used in the data to
allow other groups of researchers to analyse?
In addition to making the protocol available, the key aspects of reproducibility and
replicability in research involving data are the availability of the raw data from which
results were generated, the computer code that generated the findings, and any additional
information needed such as workflows and input parameters (Stodden, Seiler & Ma,
2018). Despite the journal policies about data sharing, only a third of computational and
data analysis could be reproduced in a straightforward way or with minor difficulty
(Stodden, Seiler & Ma, 2018). The remaining required substantial revisions for
reproduction or could not be reproduced (Stodden, Seiler & Ma, 2018).
During the analysis, the authors may have processed the data to allow analysis.
This may be in the form of transformation of data (for example log-transformation or
transformation from continuous or ordinal data into binary data), substitutions of texts
with numbers (for example intervention may be coded as 1 and control may be coded
as 0; similarly, the characteristics and/or outcomes may have been coded), or may
have used abbreviations for variable names to allow easy management and meet the
requirements for the statistical software package used. Some authors may use complex
computer codes to perform the analysis. This is different from the transformation or
substitution codes and refers to a set of computer commands that are executed sequentially
by the computer. While the authors may provide the individual subject data as part
of data sharing plan or as a journal requirement, this data is unlikely to be useful for
analysis if the transformation codes, substitution codes, abbreviations, or computer
codes are not available. Therefore, the individual participant data should be provided along
with any transformation codes, substitution codes, and abbreviations to allow other
researchers to perform analysis. The individual participant data can be provided either
as a supplementary appendix in the journal publication or can be provided in open
access repositories such as https://zenodo.org/ or university open access repositories.
This signalling question assesses whether individual subject data with sufficient details to
reanalyse were available.
DISCUSSION
Using a modified Delphi consensus process, we have developed a tool to assess the
clinical relevance of a preclinical research study in terms of the likelihood that therapeutic
preclinical research methods and findings can be translated into improvement in the
management of human diseases. We searched for existing guidelines about the design,
conduct, and reporting of preclinical research and developed domains and signalling
questions by involving experts. A modified Delphi consensus process was used to
develop new domains and signalling questions and refine the existing domains and
signalling questions to improve the understanding of the people who assess the clinical
relevance of animal research. We have included only questions for which consensus
was achieved (i.e. at least 70% of the Delphi panel members considered the question
important to evaluate the clinical relevance of animal research). This tool provides a
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framework for researchers, journal editors, grant funders, and regulatory authorities to
assess the clinical relevance of preclinical animal research with the aim to achieve better
design, conduct, and reporting of preclinical animal research.
This tool is different from the ARRIVE guidelines 2.0 (Percie du Sert et al., 2020)
and the NIH effort on improving preclinical research (National Institutes of Health, 2014)
as our tool is a domain-based assessment tool rather than a reporting guideline.
Furthermore, as opposed to a reporting guideline where the questions relate to clarity of
reporting, the questions in this tool assess the likelihood of the results being clinically
relevant. This tool is also different from the SYRCLE risk of bias of tool, as this tool goes
beyond the risk of bias in the research (Hooijmans et al., 2014). While many of the issues
have been covered by other reporting guidance on preclinical research, the issue of
measurement errors (errors in accuracy, precision, or sampling error) have not been
addressed in existing guidance on preclinical research. Measurement error in exposure or
outcome is often neglected in medical research despite the potential to cause biased
estimation of the effect of an exposure or intervention (Hernan & Cole, 2009; Brakenhoff
et al., 2018a, 2018b). Even though preclinical animal research often involves repeated
measurements, the measurement error is generally not reported or not taken into account
during the analysis. This Delphi panel arrived at a consensus that measurement errors
should be taken into account during the analysis if necessary and should be reported to
enable an assessment of whether the preclinical research is translatable to humans.
We are now piloting this tool to improve it. This is in the form of providing learning
material to people willing to pilot this tool and requesting them to assess the clinical
relevance of preclinical animal studies. Financial incentives are being offered for
piloting the tool. We intend to pilot the tool with 50 individuals including researchers
performing or planning to perform preclinical or clinical studies. If the percentage
agreement for classification of a domain is less than 70%, we will consider refining the
question, explanation, or training by an iterative process to improve the agreement.
The link for the learning material is available at: https://doi.org/10.5281/zenodo.4159278.
The tool can be completed using an Excel file, which is available in the same link.
CONCLUSIONS
We have developed a tool to assess the clinical relevance of preclinical studies. This tool is
currently being piloted.
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